New biotherapies for the treatment of cutaneous T-cell lymphomas |
| |
| Affiliation: | 1. Service de Dermatologie, Hôpital Saint-Louis, AP-HP, 1 avenue Claude Vellefaux, Paris 75010, France;2. INSERM U976, Institut de Recherche Saint-Louis, 1 avenue Claude Vellefaux, Paris 75010, France;3. Université de Paris, Paris, France;1. ENETS Center of Excellence for Neuroendocrine and Endocrine Tumors, University Hospital Basel, Basel, Switzerland;2. Department of Endocrinology, Diabetology and Metabolism, University Hospital Basel, Basel, Switzerland;3. Division of Nuclear Medicine, University Hospital Basel, Basel, Switzerland;1. L M College of Pharmacy, Department of Pharmaceutics and Pharmaceutical Technology, Navrangpura, Ahmedabad, Gujarat 380009, India;2. L.M. College of Pharmacy, Pharmacy Section, Ahmedabad, Gujarat 380058, India;1. Clinic of Dermatology, Department of Medical Sciences, University of Turin, Turin, Italy;2. Unit of Dermatology, Department of Surgery and Translational Medicine, University of Florence Medical School, Florence, Italy;3. Unit of Dermatology, Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, Italy;4. UOC Dermatologia, Dipartimento di Medicina Interna, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, University of Milan, Milan, Italy |
| |
| Abstract: | Most cutaneous lymphomas are cutaneous T-cell lymphomas, and the most common form is mycosis fungoides. Sézary syndrome is a leukemic form of cutaneous T-cell lymphoma which is characterized by erythroderma and the presence of blood tumor cells. The only potential cure of cutaneous T-cell lymphomas remains allogeneic stem cell transplantation. However, monoclonal antibodies have led to a substantial progress in the treatment of advanced-stage cutaneous T-cell lymphomas. Some of them, such as mogamulizumab (anti-CCR4 monoclobal antibody) or brentuximab vedotin (anti-CD30 coupled to monomethylauristatin E, antibody drug conjugate) have shown efficacy in international randomized controlled studies. Lacutamab, an anti-KIR3DL2 monoclonal antibody, is currently tested in an international, prospective phase 2 trial in cutaneous T-cell lymphomas and peripheral T-cell lymphomas. Finally, immune checkpoint inhibitors have shown clinical benefit in open-label phase 2 studies in cutaneous T-cell lymphomas. This review focuses on the new biotherapies currently used in cutaneous T-cell lymphomas. |
| |
| Keywords: | |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
